---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-022852"
form_type: "8-K"
ticker: "TVGN"
cik: "0001860871"
company_name: "Tevogen Bio Holdings Inc."
filed_at: "2023-06-29T23:59:59+00:00"
generated_at: "2026-06-13T15:06:33.198126+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Semper Paratus Acquisition Corp. enters definitive merger with Tevogen Bio at $1.2B enterprise value

## Summary
- Merger consideration: $1.2B in Semper Paratus Class A common stock; plus up to 20M earnout shares at price targets of $15, $17.50, $20.
- Post-closing board: 7 directors, 6 designated by Tevogen Bio; CEO and CFO of Tevogen to continue in same roles.
- Closing conditions: minimum $25M cash at close, shareholder approvals, SEC registration, and $5M net tangible assets.
- Outside date: December 5, 2023; no termination fees; equity line of credit $35M-$60M possible but not required.

## SEC filing metadata
- accession: 0001493152-23-022852
- form_type: 8-K
- ticker: TVGN
- cik: 0001860871
- company_name: Tevogen Bio Holdings Inc.
- filed_at: 2023-06-29T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1860871/000149315223022852/0001493152-23-022852-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1860871/000149315223022852/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-022852
- JSON: https://secwatch.observer/filing/0001493152-23-022852.json
- Plain text: https://secwatch.observer/filing/0001493152-23-022852.txt

## Key facts
- Material Agreements
  Tevogen Bio Holdings Inc. entered into Merger Agreement with Semper Paratus Acquisition Corporation, Semper Merger Sub, Inc., SSVK Associates, LLC (effective 2023-06-28).
  - Action: entry
  - Agreement: merger
  - Counterparty: Semper Paratus Acquisition Corporation, Semper Merger Sub, Inc., SSVK Associates, LLC
  - Effective: 2023-06-28
  source text: On June 28, 2023, Semper Paratus Acquisition Corporation, a Cayman Island exempted company (“ Semper Paratus ”) entered into an Agreement and Plan of Merger by and among Semper Paratus, Semper Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Semper Paratus (“ Merger Sub ”), SSVK Associates, LLC, Semper Paratus’ sponsor (the “ Sponsor ”), in its capacity as purchaser representative, Tevogen Bio Inc, a Delaware corporation (“ Tevogen Bio ”), and Ryan Saadi, in his capacity as seller representative (as may be amended and/or restated from time to time, the “ Merger Agreement ”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1860871/000149315223022852/0001493152-23-022852-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.